Medical Technology Transfer and Services
Medical Technology Transfer and Services
Bringing access to appropriate medical treatment for neonatal patients across several countries in Africa, targeting the poorest and most remote hospitals in rural areas.
BCTA MEMBERSHIP STATUS
Active
SECTOR
Health
HEADQUARTERS
Vietnam
REGION OF INITIATIVE
Africa
SDG CONTRIBUTION
RELATED NEWS
Medical devices designer and manufacturer Medical Technology Transfer and Services (MTTS) joined Business Call to Action (BCtA) in March 2019 with a commitment to deliver access to neonatal treatment for 495,000 low income patients in 10 African countries through the delivery of devices to 200 hospitals. MTTS aims to meet their goal by 2022.
The first 28 days of life (the neonatal period) is considered to be the time when children are most vulnerable to illness and death due to poor medical care and diseases. The United Nations International Children's Emergency Fund (UNICEF) says that in 2017, about 2.5 million children died in 30 days after birth. This can be seen in West and Central Africa and South Asia, with each region having an estimated 27 deaths per 1,000 live births in 2017, despite the global decline in the neonatal mortality rate.
As the cost of medical devices for neonatal care is a significant contributor to these high mortality rates, MTTS sought to design new medical technologies that would be low cost, washable and reusable for use in the poorest regions, especially in the company’s home country Vietnam. MTTS’ CEO Gregory Dajer explained that after examining global health needs, it was clear that the company’s products were needed in many countries, especially in the African continent.
Based on the need for affordable healthcare, MTTS has signed on to the BCtA as it seeks to participate in the global movement to meet the Sustainable Development Goals (SDGs), with focus placed on SDG 3 and SDG 10. As part of this commitment, low income patients in Nigeria, Zimbabwe, Burkina Faso, Togo, Benin, Senegal, Ghana, Kenya, Uganda and Tanzania will benefit from treatment by 2022.